佰乐博生物蛋白抗体推荐Trastuzumab蛋白抗体，曲妥珠单抗
一、中文名称：曲妥珠单抗
二、产品描述：Trastuzumab在过表达HER2的肿瘤细胞中发挥特异性抗肿瘤活性。Trastuzumab与HER2的近膜区结合，一旦与受体结合，这个抗体可下调HER2的表达。Trastuzumab选择性地抑制不依赖于配体的HER2-HER3二聚化。除此之外，trastuzumab与HER2结合可抑制HER2胞外区域的溶蛋白性裂解，导致p95-HER2水平降低。trastuzumab可导致PI3K信号通路和下游细胞周期进展相关介质如cyclin D1下调。Trastuzumab不仅抑制HER2信号通路，同时也在HER2过表达细胞中引起免疫相关反应。Trastuzumab的结合占用了免疫效应细胞上的Fc受体，导致抗体依赖性的细胞毒性。因此，trastuzumab具有抗血管生成的作用，降低化疗凋亡阈值。
三、产品详情：
货号：DHC09601
表达系统：Mammalian Cells
种属反应性：Human
宿主：Humanized
同种型：IgG1-kappa
克隆类型：Monoclonal
靶标：p185erbB2, HER2, NGL, Tyrosine
kinase-type cell surface receptor HER2, NEU, MLN 19, Proto-oncogene Neu, MLN19,
ERBB2, Proto-oncogene c-ErbB-2, CD340, Receptor tyrosine-protein kinase erbB-2,
Metastatic lymph node gene 19 protein
浓度：2.6 mg/ml
内毒素水平：Please contact with the lab
for this information.
纯度：>95% as determined by
SDS-PAGE.
纯化方式：Protein A/G purified from cell
culture supernatant.
Accession 号：P04626
克隆号：Trastuzumab
应用：Research Grade Biosimilar
状态：Liquid
保存溶液：0.01M PBS, pH 7.4.
稳定性和存储：Use a manual defrost freezer
and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks).
Store at -20°C 12 months. Store at -80°C long term.
别名：timigutuzumab, 4D5-8, 4D5V8,
Herceptin, rhuMab HER2, CAS: 180288-69-1
四、参考文献：
1. Quality-adjusted time without
symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab
emtansine in HER2- positive metastatic breast cancer patients based on
secondary use of the DESTINY-Breast03 trial. PMID: 39798264
2. Clinical Treatment Score Post-5
Years (CTS5) and Late Recurrence Risk in Hormone Receptor-Positive,
HER2-Positive Breast Cancer. PMID: 39191270
3. Local Therapy Outcomes and Toxicity
From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant
Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in
Women With Stage I HER2-Positive Breast Cancer. PMID: 34990776
4. Seven-Year Follow-Up Analysis of
Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal
Growth Factor Receptor 2-Positive Breast Cancer. PMID: 30939096
5. First-line pembrolizumab and
trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal
junction cancer: an open-label, single-arm, phase 2 trial. PMID: 32437664
6. Early endpoints of a randomized
phase II trial of preoperative chemotherapy with S-1/CDDP with or without
trastuzumab followed by surgery for HER2-positive resectable gastric or
esophagogastric junction adenocarcinoma with extensive lymph node metastasis:
Japan Clinical Oncology Group study JCOG1301C (Trigger Study). PMID: 38243037
7. Clinical and imaging features of
interstitial lung disease in cancer patients treated with trastuzumab
deruxtecan. PMID: 37787866
8. Final results of DESTINY-CRC01
investigating trastuzumab deruxtecan in patients with HER2-expressing
metastatic colorectal cancer. PMID: 37286557
详情请咨询Antibodysystem中国授权总代理-武汉佰乐博生物技术有限公司
网址：https://www.biolabreagent.com/product/99/3947.html
武汉佰乐博生物技术有限公司作为法国Antibodysystem品牌亚洲区授权总代理。提供近3万种蛋白、抗体等核心生命科学试剂，旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。
试剂 | 耗材 | 定制 | 实验服务 | 供应链
免费热线：027-65279366 /18108604356
